Pediatric precursor B-cell acute lymphoblastic leukemia with MYC 8q24 translocation - how to treat?

Leuk Lymphoma. 2018 Aug;59(8):1807-1813. doi: 10.1080/10428194.2017.1387914. Epub 2017 Oct 12.

Abstract

Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. Within ALL, precursor B-cell disease predominates and now has survival >90%. Mature B-cell, or Burkitt leukemia/lymphoma, is distinct from ALL and requires short intensive chemotherapy and with the addition of Rituximab, survival rates of >95% are achieved. Its defining characteristic is MYC translocation at 8q24. Patients who have features of both ALL and Burkitt leukemia/lymphoma represent a rare subpopulation of ALL and present a diagnostic and treatment conundrum. We have performed a systematic review on the occurrence of and treatment of MYC positive precursor B-ALL, reported between 1980 and 2016. The review highlighted a lack of data to guide any consensus about how to treat this important group of children and focused research in this area is needed.

Keywords: MYC; Pediatric; acute lymphoblastic leukemia; precursor B.

Publication types

  • Systematic Review

MeSH terms

  • Burkitt Lymphoma / genetics
  • Burkitt Lymphoma / metabolism
  • Burkitt Lymphoma / therapy
  • Child
  • Chromosomes, Human, Pair 8 / genetics*
  • Humans
  • Immunophenotyping
  • Karyotyping
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Proto-Oncogene Proteins c-myc / genetics*
  • Translocation, Genetic*

Substances

  • Proto-Oncogene Proteins c-myc